Secretome Therapeutics Doses First Patient in Phase 1 Trial of STM-01 for HFpEF

Secretome Therapeutics has shared an update. The clinical-stage biotechnology company announced dosing of the first patient in its Phase 1 trial of STM-01, an allogeneic, off-the-shelf stem cell therapy derived from neonatal cardiac progenitor cells, for the treatment of heart failure with preserved ejection fraction (HFpEF). This first-in-human, multiple-ascending dose, open-label study will evaluate safety, tolerability, and exploratory efficacy in HFpEF patients, with dosing at 100 million or 200 million cells via intravenous infusion. The trial’s first patient was enrolled at the University of Texas Southwestern Medical Center under the care of Dr. Ambarish Pandey, with scientific leadership also highlighted from Northwestern University’s HFpEF program.

For investors, the initiation of this Phase 1 study marks a key clinical inflection point for Secretome Therapeutics, transitioning STM-01 from preclinical to human testing in a large and underserved cardiovascular indication. HFpEF accounts for at least half of heart failure cases in the U.S., representing a substantial commercial opportunity if STM-01 demonstrates safety and meaningful clinical benefit. Management notes recent progress including securing multiple STM-01 patents, launching large-scale GMP manufacturing, and completing a seed financing round, which together suggest a strengthening IP position and enhanced development readiness. However, STM-01 remains at an early stage, with typical Phase 1 risks around safety, clinical signal, and future capital requirements. Successful early results could improve the company’s ability to attract larger financing rounds or strategic partnerships in the competitive cardiovascular and cell therapy landscape, while setbacks or safety concerns could materially delay development and increase funding risk.